Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents

Bosnjak, Berislav; Odak, Ivan; Barros-Martins, Joana; Sandrock, Inga; Hammerschmidt, Swantje I.; Permanyer, Marc; Patzer, Gwendolyn E.; Greorgiev, Hristo; Gutierrez Jauregui, Rodrigo; Tscherne, Alina; Schwarz, Jan Hendrik; Kalodimou, Georgia; Ssebyatika, George; Ciurkiewicz, Malgorzata; Willenzon, Stefanie; Bubke, Anja; Ristenpart, Jasmin; Ritter, Christiane; Tuchel, Tamara; Meyer zu Natrup, Christian; Shin, Dai-Lun; Clever, Sabrina; Limpinsel, Leonard; Baumgaertner, Wolfgang; Krey, Thomas; Volz, Asisa; Sutter, Gerd und Foerster, Reinhold (11. November 2021): Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. In: Frontiers in Immunology, Bd. 12, 772240

Abstract

Antigen-specific tissue-resident memory T cells (Trms) and neutralizing IgA antibodies provide the most effective protection of the lungs from viral infections. To induce those essential components of lung immunity against SARS-CoV-2, we tested various immunization protocols involving intranasal delivery of a novel Modified Vaccinia virus Ankara (MVA)-SARS-2-spike vaccine candidate. We show that a single intranasal MVA-SARS-CoV-2-S application in mice strongly induced pulmonary spike-specific CD8+ T cells, albeit restricted production of neutralizing antibodies. In prime-boost protocols, intranasal booster vaccine delivery proved to be crucial for a massive expansion of systemic and lung tissue-resident spike-specific CD8+ T cells and the development of Th1 - but not Th2 - CD4+ T cells. Likewise, very high titers of IgG and IgA anti-spike antibodies were present in serum and broncho-alveolar lavages that possessed high virus neutralization capacities to all current SARS-CoV-2 variants of concern. Importantly, the MVA-SARS-2-spike vaccine applied in intramuscular priming and intranasal boosting treatment regimen completely protected hamsters from developing SARS-CoV-2 lung infection and pathology. Together, these results identify intramuscular priming followed by respiratory tract boosting with MVA-SARS-2-S as a promising approach for the induction of local, respiratory as well as systemic immune responses suited to protect from SARS-CoV-2 infections.

• Dokumententyp: Zeitschriftenartikel
• Keywords: Bronchus-associated lymphoid tissue (BALT); lungs; modified vaccinia virus Ankara (MVA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); spike (S) protein; vaccine; vaccination; respiratory tract
• Fakultät: Tiermedizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1664-3224
• Sprache: Englisch